• About Us
    • Overview
    • Leadership Team
    • History
    • Contact Us
  • Science
    • Our Approach
    • Technology Platforms
    • Publications
  • Pipeline
    • Pipeline
  • Investors
    • CURACLE News
    • Notices
    • Disclosures
    • IR Materials
    • FAQ
  • Careers
    • Careers
KOR ENG
  • About Us
    • Overview
    • Leadership Team
    • History
    • Contact Us
  • Science
    • Our Approach
    • Technology Platforms
    • Publications
  • Pipeline
    • Pipeline
  • Investors
    • CURACLE News
    • Notices
    • Disclosures
    • IR Materials
    • FAQ
  • Careers
    • Careers

Investors

Home ›Investors ›CURACLE News

CURACLE News

No
Category
Title
Date
  • 6
    Media
    Curacle’s CU01 adds further proteinuria reduction when paired with standard treatment, emerging as a new option with safety profile
    2026-10-16
  • 5
    Media
    Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Dise…
    2026-06-19
  • 4
    Media
    Curacle Receives Upfront Payment from Global Licensing Deal for MT-103
    2026-06-05
  • 3
    Media
    Curacle Shares Rise for Second Straight Day on Up to 1.6 Trillion Won Licensing Deal
    2026-05-12
  • 2
    Media
    Curacle–MabTics Execute Global Licensing Agreement for Retinal Bispecific Antibody MT-103
    2026-05-11
  • 1
    Media
    Curacle files PCT international patent application for ‘CU71,’ a ‘BBB stabilizer’ Alzheimer’s new drug candidate
    2025-07-23
About Us Science Pipeline Investors Careers
Partners
MabTics Memento Medicines

로고 CONTACT
telegram blog youtube
23-1, Hyoryeong-ro, Seocho-gu, Seoul, 06694, Republic of Korea curacle_info@curacle.com

Copyright © 2025 curacle | All Rights Reserved